Patients with systemic health or controlled medical conditions with single bone-level, tapered implants with Straumann Bone Level Taper (BLT) or Neodent Helix GM bone-level, tapered implants Straumann Bone Level Taper (BLT) Neodent Helix GM
Conditions
Interventions
Patients receiving single Straumann Bone Level Tapered (BLT) implants.,Patients receiving single Neodent Helix GM implants.
Other,Other
Straumann Bone Level Tapered (BLT),Neodent Helix GM
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients older than 18 years 2. Patients receiving single bone-level, tapered implant placement with Straumann Bone Level Taper (BLT) or Helix GM 3. Patients with systemic health or controlled medical conditions 4. Patients attending all the follow-ups visits (6 months, 1 year) 5. Insertion torque at implant placement visit not greater than 35 Ncm and not less than 10 Ncm 6. Implants placed in ideal position: at least a minimum of 1.5 mm from the adjacent tooth structure, at least a minimum of 2 mm present from implant neck to adjacent tooth coronally, adequate surrounding bucco-lingual bone width, and ideal angulation bucco-lingually and mesio-distally 7. Presence of parallel long-cone periapical radiographs from each of the time points to be evaluated in this study: baseline (T0) (i.e., at the time point of implant placement or at the immediately following recall appointment of 2 weeks), at follow-up visits of 6 months (T1), and 1 year (T2) after implant placement
Exclusion criteria
Exclusion criteria: 1. Patients with records of any previous medical condition, disease, or intake of medication known to alter bone remodeling because of the establishment of biological bone metabolism 2. Patients with previous radiotherapy in the head and neck area 3. Patients with non-treated periodontal disease in the remaining teeth 4. Patients undergoing simultaneous procedure of bone graft, guided bone regeneration, or sinus lift during implant placement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Marginal bone loss 6 months, 1 year after implant placement millimeters | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain and tenderness upon function 1 year after implant placement presence/absence,Mobility 1 year after implant placement Mobility scale of 0,1,2,3,History of exudate 1 year after implant placement presence/absence | — |
Countries
Thailand
Contacts
Public ContactKanyarak Kunyawatyuwapong
Chulalongkorn University
Outcome results
None listed